What is Corvus Pharmaceuticals, Inc.'s Market Cap?

Corvus Pharmaceuticals, Inc.'s Market Cap is $1.2B, based on as-reported figures from SEC (XBRL) filings.

What is Corvus Pharmaceuticals, Inc.'s Enterprise Value?

Corvus Pharmaceuticals, Inc.'s Enterprise Value is $1.2B, based on as-reported figures from SEC (XBRL) filings.

What is Corvus Pharmaceuticals, Inc.'s EV / EBITDA?

Corvus Pharmaceuticals, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Corvus Pharmaceuticals, Inc.'s Net Income (TTM)?

Corvus Pharmaceuticals, Inc.'s Net Income (TTM) is -$54.1M, based on as-reported figures from SEC (XBRL) filings.

What is Corvus Pharmaceuticals, Inc.'s EBITDA?

Corvus Pharmaceuticals, Inc.'s EBITDA is -$56.8M, based on as-reported figures from SEC (XBRL) filings.

What is Corvus Pharmaceuticals, Inc.'s Diluted EPS (TTM)?

Corvus Pharmaceuticals, Inc.'s Diluted EPS (TTM) is -0.64, based on as-reported figures from SEC (XBRL) filings.

What is Corvus Pharmaceuticals, Inc.'s Net Debt?

Corvus Pharmaceuticals, Inc.'s Net Debt is -$18.9M, based on as-reported figures from SEC (XBRL) filings.

Corvus Pharmaceuticals, Inc. (CRVS) Financial Statements

Corvus Pharmaceuticals, Inc.

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG009F0TGJ6

XNAS · usd

14.07▲ 0.14 (1.01%)

As of 2026-09-09

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales—

EV / Revenue—

EV / EBITDA

Financial Highlights

Revenue (TTM)—

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin—

Net Debt

Trading Information

Previous Close13.93

Day's Range13.85 – 14.32

52-Week Range5.64 – 26.95

Volume1.0M

Avg Volume747.7K

Share Statistics

Shares Outstanding

Employees37

ExchangeXNAS

Listed2016-03-23

Share count as of August 6, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Corvus Pharmaceuticals, Inc. (CRVS)

What is Corvus Pharmaceuticals, Inc.'s Market Cap?: Corvus Pharmaceuticals, Inc.'s Market Cap is $1.2B, based on as-reported figures from SEC (XBRL) filings.
What is Corvus Pharmaceuticals, Inc.'s Enterprise Value?: Corvus Pharmaceuticals, Inc.'s Enterprise Value is $1.2B, based on as-reported figures from SEC (XBRL) filings.
What is Corvus Pharmaceuticals, Inc.'s EV / EBITDA?: Corvus Pharmaceuticals, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Corvus Pharmaceuticals, Inc.'s Net Income (TTM)?: Corvus Pharmaceuticals, Inc.'s Net Income (TTM) is -$54.1M, based on as-reported figures from SEC (XBRL) filings.
What is Corvus Pharmaceuticals, Inc.'s EBITDA?: Corvus Pharmaceuticals, Inc.'s EBITDA is -$56.8M, based on as-reported figures from SEC (XBRL) filings.
What is Corvus Pharmaceuticals, Inc.'s Diluted EPS (TTM)?: Corvus Pharmaceuticals, Inc.'s Diluted EPS (TTM) is -0.64, based on as-reported figures from SEC (XBRL) filings.
What is Corvus Pharmaceuticals, Inc.'s Net Debt?: Corvus Pharmaceuticals, Inc.'s Net Debt is -$18.9M, based on as-reported figures from SEC (XBRL) filings.